A phase III placebo-controlled study followed, using induction and consolidation chemotherapy regimens combined with midostaurin, and followed by one year maintenance with midostaurin in 717 patients with newly diagnosed FLT3 mutated AML (ITD or TKD) [35]. Here, FLT3 is linked to acute myeloid leukemia.